Dengvaxia®: Protective value for people with at least one prior dengue infection confirmed; vaccinating people without prior infection not recommended

New England Journal of Medicine announced the effect of Dengue serum on the safety and efficacy of dengue vaccine on 13th June 2018. This article provides a comprehensive analysis of long-term clinical data of dengue vaccine that is shared with dengue vaccine. Announcement of last November

This new publication suggests that this vaccine may prevent dengue, particularly severe dengue (84%) and dengue hospital (80%) during the five-year follow-up period for individuals over 9 years of age Check. Infection findings were also fully documented and approved by various experts, including the WHO vaccination specialist strategy advisory group who announced the latest recommendations on vaccine use in the weekly epidemiological report on 8th June 2018 . .

Dengue is the fastest growing mosquito-borne disease in the world today, with an estimated 1 million new infections per day. Severe dengue fever is generally rare and only 0.5% of all symptomatic cases occur, but secondary viral infections are more likely to develop more serious disease than the first infection. This unique feature of dengue infection is important to understand the new data on dengue vaccines discussed in the New England Journal of Medicine article. In this supplemental analysis, we found that the incidence of severe illness has increased for people who have not been vaccinated compared with people who have not received vaccination without being vaccinated.

For research participants above 9 years of age who were not infected, the relative risk of severe dengue fever following vaccination after mosquito biting was comparable to the risk of non vaccinated secondary infection. More importantly, the severity of the illness of vaccinated individuals responds well to medical care, and all individuals are fully recovered.

Based on the findings reported in November 2017, sanofi pasteur has contacted the regulatory authorities of the country currently receiving vaccine approval and recommended vaccine to recommend use in previous dengue fever infections and warned individuals We recommend updating prescription information. The opposite vaccination against those who are not infected in advance. Currently, some countries have decided to promote the renewal of labels and are still under review in other countries.

In sharing new data on our dengue vaccine, sanofi pasteur has spread the complex science in an easy-to-understand manner, increasing the importance of protecting unnecessary concerns and proper public safety against vaccines . Misunderstanding about validity.

Sanofi pasteur has long worked on the global struggle against dengue. Since every effort is made to provide dengue vaccine use to those who have experienced at least one dengue infection, they can benefit from the high level protection of the vaccine against subsequent dengue infection.

"This analysis has confirmed that ensenza has a sustained protective effect against the dengue fever of previously infected people, but for those who have never been infected with dengue virus before, the analysis is long-term There may be more serious vaccination cases of illness, then dengue fever infection, "sanofi said

Dengue is the fastest growing mosquito-borne disease in the world today, with an estimated 1 million new infections per day. Severe dengue fever is generally rare and only 0.5% of all symptomatic cases occur, but the secondary infection of the virus is more likely to develop into a more serious disease than the first infection. This unique feature of dengue infection is important to understand the new data on dengue vaccines discussed in the New England Journal of Medicine article. This supplemental analysis showed that vaccinated individuals had a higher incidence of serious diseases without prior infection compared with those who were not vaccinated.

Dengvaxia®: We are confirming the preventive effect of at least one Dengue infected person; vaccination is not recommended for those who have not previously been infected

Previous exposure to dengue was not protective, but it can enhance the phenomenon known as subsequent infection, antibody dependent enhancement (ADE). Experts such as Dr. Scott Halstead and MD clearly show that ADE was caused among people who were not vaccinated at the onset of dengue fever, according to Denkaxia data. More than two years ago, he suggested that this vaccine can not be used for children and dengue fever.